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Objectives:
 
 Clinical trials indicate enoxaparin thrombo-
prophylaxis (Clexane) can be effective and safe when
used in an outpatient setting and that extending the
length of thromboprophylaxis with enoxaparin to the
postdischarge period may be more effective than inpa-
tient thromboprophylaxis alone. This may increase the
cost of thromboprophylaxis. The objective of the study
was to estimate the expected cost-effectiveness of us-
ing enoxaparin for hospital admission only vs. enox-
aparin for hospital admission and for 21 days postdis-
charge.
 
Methods:
 
 Decision analysis was used to combine prob-
ability, resource use and unit cost data, using the frame-
work of cost-effectiveness analysis. The model used a
societal perspective to estimate the expected costs of
treatment and outcomes to patients undergoing ortho-
pedic surgery for elective hip replacement. Incremental
cost-effectiveness ratios were calculated to provide esti-
mates of the cost per life gained, cost per year life year
gained and cost per quality-adjusted life year gained
with extended use of enoxaparin thromboprophylaxis.
 
Results:
 
 There was an expected cost per quality-adjusted
 
life year gained of £
 
5732 associated with extended
enoxaparin thromboprophylaxis. The results were sen-
sitive to the percentage of patients who could adminis-
ter enoxaparin injections at home, the rate of DVT as-
sociated with standard enoxaparin thromboprophylaxis
and the rate of PE associated with standard and ex-
tended enoxaparin thromboprophylaxis.
 
Conclusions:
 
 The analyses indicated that in most cases
extended enoxaparin thromboprophylaxis resulted in
increased costs for health care services. In all cases, ex-
tended thromboprophylaxis with enoxaparin was asso-
ciated with improved survival and life-years gained.
 
Keywords:
 
 DVT, economics, enoxaparin, postdischarge,
thromboprophylaxis.
 
Introduction
 
Deep Vein Thrombosis (DVT) is a common com-
plication of major surgery or serious illness. DVT
is associated with a number of sequelae and events
that are clinically important and affect patient sur-
vival and quality of life. These include fatal and
nonfatal pulmonary embolism (PE), recurrence of
thromboembolic events and long-term complica-
tions such as the post–thrombotic syndrome [1,2].
The postoperative risk of fatal PE is uncertain
with estimates ranging from 0.1% to 5% [3,4].
The risk of DVT and its complications continues
for at least several weeks postoperatively.
The resource use associated with diagnosis and
treatment of DVT is significant, not least because
the length of inpatient stay following surgery can
be considerably increased. In addition, readmis-
sion may be required. Because of the cost, morbid-
ity and mortality associated with the sequelae of
DVT, thromboprophylaxis with mechanical meth-
ods, unfractionated heparin (UFH) or low molecu-
lar weight heparin (LMWH) is an important com-
ponent of clinical guidelines in the UK [e.g. 5,6].
The method of thromboprophylaxis depends
on the likely risk of DVT, which varies between
patient groups, and surgical procedures. For pa-
tients, undergoing elective hip replacement, who
are at high risk of DVT, chemical thromboprophy-
laxis with UFH or LMWH is recommended [1,4–6].
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Furthermore, evidence suggests that LMWH is an
effective and cost-effective prophylaxis for the
prevention of DVT in this high risk group [7–15].
Recently, clinical trials have also indicated that
LMWH is an effective and safe treatment for DVT
when administered at home rather than hospital
[16,17].
Late venous complications occur because of
prolonged impaired hemostasis and hemodynam-
ics, postsurgical venous injury and poor mobiliza-
tion following discharge. Recent clinical evidence
suggests that extending the length of thrombopro-
phylaxis with LMWH to the postdischarge period
may be more effective than inpatient thrombopro-
phylaxis alone [18–21].
In the UK, thromboprophylaxis has become an
important part of surgical patient management,
pre- and postoperatively [22,23]. A recent UK sur-
vey indicated that 99% of surgeons used routine
thromboprophylaxis for patients undergoing elec-
tive hip replacement and 79% used a combination
of mechanical and chemical methods. Nearly two
thirds of respondents routinely used LMWH for
chemical thromboprophylaxis [23]. For the UK,
the extent to which patients receive thrombopro-
phylaxis on discharge from hospital is unclear. A
recent study in the US indicated that approxi-
mately 60% of patients who had elective hip re-
placement surgery were discharged with some form
of thromboprophylaxis. Of these, LMWH was
prescribed for about a third of patients [24].
Extended thromboprophylaxis with LMWH
would increase the drug costs of elective hip replace-
ment. However, recent economic analyses indicate
that extended thromboprophylaxis with enoxaparin
may be cost-effective in Sweden and France, by re-
ducing the incidence of postdischarge DVT and
hospital readmissions [25,26]. The aim of this pa-
per is to assess the expected cost-effectiveness in
the United Kingdom of enoxaparin used for ex-
tended prophylaxis postdischarge for DVT in hip
surgery compared to enoxaparin administration
prior to hospital discharge only.
 
Methods
 
The objective of the study was to estimate the incre-
mental expected cost-effectiveness of using enox-
aparin for the index hospital admission and 21 days
postdischarge (extended enoxaparin) compared to
using enoxaparin for the index hospital admission
only (standard enoxaparin). The 21-day postdis-
charge period for extended enoxaparin was chosen
to reflect the timing of the primary assessment in
the clinical trial used for the analysis [18].
The study addresses a limited question in the
management of patients undergoing elective hip
replacement. That is, whether extended thrombo-
prophylaxis with enoxaparin is cost-effective com-
pared to no extended thromboprophylaxis in the
UK setting. It is important to assess whether the find-
ings of economic evaluations of extended enox-
aparin also apply in the UK, particularly if patients
do not routinely receive thromboprophylaxis on
discharge from hospital following elective hip re-
placement surgery. In addition, there is insuffi-
cient clinical evidence to compare the relative ef-
fectiveness of enoxaparin with alternative methods
of extended thromboprophylaxis after hospital dis-
charge, for this patient group.
A societal perspective was used [27,28]. In the
United Kingdom the key components for this per-
spective are the costs to the National Health Service
(NHS) of providing treatment and care and the out-
comes to patients. The NHS is funded by general
taxation and is the principal provider of health
care, which is free at the point of consumption.
The model only considered the expected cost-
effectiveness for patients undergoing orthopaedic
surgery for elective hip replacement. Decision anal-
ysis was used to combine probability, resource use
and unit cost (price) data [8]. This approach al-
lowed a range of clinical alternatives and clinical
outcomes to be described and expected costs and
consequences to be estimated.
Figure 1 presents the decision tree for events and
management choices. The decision tree starts at the
point at which the decision has been taken to give
enoxaparin prophylaxis against DVT. The choice is
then between extended enoxaparin and standard
enoxaparin. There is insufficient evidence to support
differences in the sequence of events between the two
choices, which are therefore assumed to be identical.
On this basis, only the extended enoxaparin arm is
illustrated in full. However, clinical trials evidence
does suggest that the probability of one or more sub-
sequent events may differ between the two choices
[18,19]. The decision tree extends the model devel-
oped for the UK setting, which was used in a previ-
ous economic analysis of enoxaparin [8].
The expected costs and benefits of the standard
and extended regimes of thromboprophylaxis were
estimated for a cohort of 1000 patients undergoing
elective hip replacement. The expected outcomes
of thromboprophylaxis were estimated using three
measures. These were lives gained, life-years gained
and quality-adjusted life-years gained.
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The costs of events were estimated as the quan-
tity and type of health care resources used, multi-
plied by the unit costs or prices of those resources.
All estimates of unit cost were for 1997–8 prices.
Where necessary, unit costs were inflated to 1997–
98 prices using the Hospital and Community Health
Services Index [29].
The costs included in the analysis were for ex-
tended thromboprophylaxis and treatment of events
within the 21-day postdischarge period. It was not
necessary to discount this. The long-term patient
outcomes of life-years gained and QALYs were
discounted to present values. The discount rate for
the base case analysis was 1.5% (the rate recom-
mended by the UK Treasury). In the sensitivity
analysis, these were varied between 0% and 5%
[27,28].
The data for the model were based on point es-
timates from a variety of sources. However, there
was insufficient information to generate plausible
distributions for the data. This meant that it was
not possible to use statistical techniques to assess
the level of uncertainty associated with the results.
This could arise from uncertainty in the data used,
such as the probability of DVT from a limited
number of trials, or imprecision in the measure-
ment or estimation of data, such as the resources
used to treat DVT.
Sensitivity analysis was used to test the impact
on the results of changing those variables where
the use of a minimum or maximum value would
increase the cost and/or decrease the benefits asso-
ciated with extended enoxaparin.
 
Clinical Trials Data
 
Two randomized, double-blind, placebo-controlled
trials have been conducted to evaluate the out-
come of extended enoxaparin thromboprophylaxis
in patients undergoing elective hip replacement
[18,19]. In both trials, patients were given enox-
aparin 40 mg once daily by subcutaneous injec-
tion for the index hospital admission. Prior to dis-
charge, patients were randomized to receive either
once daily 40 mg enoxaparin subcutaneous injec-
tion or a placebo (saline) injection on an outpa-
tient basis for 21 days. All patients were evaluated
at follow up using objective tests (bilateral venog-
raphy). Both trials found statistically significant
differences in the rates of DVT between active and
placebo groups in favour of extended enoxaparin.
Figure 1 Decision path for the management of elective hip surgery at discharge.
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No statistically significant differences in adverse
events were found in either trial. However, the
sample sizes were calculated to detect differences
in the rate of DVT, not adverse events. There were
a number of key differences in the design of the
trials that meant that the trial by Bergqvist et al.
[18] was a more appropriate source of clinical data
for an economic analysis in the UK setting. The
trial by Planes et al. [19] used bilateral ascending
venography on all patients prior to discharge fol-
lowing surgery and subsequent enrollment in the
trial. Patients who did not have a normal veno-
gram were excluded from the study. The use of ve-
nography was specific to the trial and not common
practice [18,30]. In addition, it has been argued
that venography may be a confounding factor in
the analysis of differences between the interven-
tion and control groups [18,30]. In contrast, Berg-
qvist et al. did not use an objective test to assess
patients’ thromboembolic status prior to discharge
from the index admission.
Secondly, the trial by Planes et al. [19] only in-
cluded patients who could walk without assis-
tance other than crutches. It has been suggested
that the incidence of DVT in the control group
was high for this subset of patients undergoing
elective hip replacement, given the strict eligibility
criteria [30].
 
Probability of Events
 
For the base case analysis, data on the probability
of confirmed DVT, PE, and hospital readmission
were estimated from the Bergqvist et al. trial [18]
comparing standard and extended enoxaparin (Ta-
ble 1). For the sensitivity analysis, the minimum
and maximum rates of DVT for both standard
and extended enoxaparin thromboprophylaxis were
assumed to be between 18% and 39%. These are
the rates of DVT found in the clinical trial by
Bergqvist et al. [18]. In addition, the sensitivity
analysis used the rates of DVT and PE from the
Planes et al. trial [19], to assess the impact of a
lower incidence of DVT on the results.
The probability of clinically and economically
important DVT may have been over-estimated in
the clinical trial, which used objective diagnosis to
detect all DVTs. To adjust the objectively diag-
nosed rates of DVT, the decision tree included the
probability that the patient had signs and symp-
toms of DVT allowing a clinical diagnosis to be
made. The probabilities of a clinical diagnosis of
PE, accuracy of clinical diagnosis and survival
were taken from the previous economic analysis of
enoxaparin in the UK [8], which were also used in
the economic evaluation of extended enoxaparin
in the French setting [26].
 
Patient Outcomes
 
The number of lives gained per 1000 cohort of pa-
tients undergoing elective hip replacement with
extended enoxaparin was calculated as 1000 mul-
tiplied by the net expected probability of survival.
The number of life-years gained with extended
enoxaparin was calculated as the number of lives
gained following surgery multiplied by the average
life expectancy for the cohort. The average (me-
dian) age at surgery of patients enrolled in the
clinical trial used for this analysis was 70 [18].
The life expectancy of people aged 70 was esti-
mated to be 81 years using national statistics for
the UK [31].
National surveys conducted for the government
Office of National Statistics [32] indicate that the
self-reported general health of the population de-
clines with age. In the 1998 survey, 78%–86% of
people aged 16–54 reported their general health to
be good or very good, compared to 57%–68% of
people aged 55 years or over. In addition, 52%–
66% of people over the age of 55 reported a long-
standing illness compared to 22%–37% of people
aged 16–54.
These data, and the older age of the population
for this analysis, indicate that gains in survival and
life-years from the use of extended enoxaparin
will over-estimate the potential health gains which
could be realized. Therefore, the number of life-
years gained were weighted by an age-specific
health-related utility value to estimate quality-
adjusted life-years (QALYs) gained. The utility
values used for the analysis were those reported by
a national survey of self-reported health status
and health-related quality of life [33]. The instru-
ment used in the survey was the EuroQol, a vali-
dated measure of health status and utility. The
utility weights reported were generated from a
population survey using the time trade off tech-
nique. It was assumed that the utility value would
be the same for DVT/PE and non-DVT/PE pa-
tients. This reduces the potential QALY gain from
any reductions in nonfatal DVT or PE that may be
associated with the use of extended enoxaparin.
 
Resource Use
 
A search of the literature was conducted to esti-
mate the use of inpatient and community-based
health care services that were specific to the UK
setting (Table 2). For the base case analysis, it was
estimated that all patients with symptoms of DVT
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or PE would have objective diagnostic evaluations
to confirm the clinical diagnosis [8].
Furthermore, it was estimated that asymptom-
atic patients would not have objective tests to de-
tect DVT or PE [8]. The rate of readmission for
the diagnosis and treatment of DVT occurring in
the community and the average length of stay per
readmission was estimated from observed rates re-
 
Table 1
 
Probability of events
 
Extended enoxaparin thromboprophylaxis* Standard enoxaparin thromboprophylaxis*
Rate of thrombosis
DVT [18] 0.18 (0.18–0.39) 0.39 (0.18–0.39)
PE [8,18,19] 0.00 (0.00–0.12) 0.04 (0.00–0.12)
Clinical symptoms & diagnosis
DVT [18] 0.10 (0.10–0.19) 0.19 (0.10–0.19)
PE, true DVT, true PE [8] 0.29 0.29
PE, true DVT, false PE [8] 0.02 0.02
PE, no DVT [8] 0.02 0.02
Survives PE 1 hour [8] 0.89 0.89
Treatment, objective test positive [8] 1.00 1.00
Survival
Treated and untreated DVT [8] 0.99 0.99
No DVT [8] 1.00 1.00
Treated PE [8] 0.92 0.92
Untreated PE [8] 0.70 0.70
Re-admission for treatment
DVT, given DVT [18] 0.52 0.71
PE, given PE
 
†
 
1.00 1.00
 
*Base case estimates, numbers in parentheses are minimum and maximum values for the sensitivity analysis.
 
†
 
Assumed value. DVT, deep vein thrombosis; PE, non-fatal pulmonary embolism.
 
Table 2
 
Resource use: thromboprophylaxis, diagnosis and treatment
 
Average resource use (range)
DVT* PE* Unit costs (range) £’
 
s, 1997–98*
Thromboprophylaxis, post-discharge
Enoxaparin (no. injections) [36] 21 21 4.52
District nurse visits [29] 21 (0–21)
 
†
 
21 (0–21)
 
†
 
13 (8–17)
GP visits [29] 3
 
†
 
3
 
†
 
10 (10–45)
Blood platelet count [37,39] 3
 
†
 
3
 
†
 
3 (3–4)
No thromboprophylaxis, post-discharge
District nurse visits [29] 3 (0–3)
 
†
 
3 (0–3)
 
†
 
13 (8–17)
GP visits [29] 3
 
†
 
3
 
†
 
10 (10–45)
Confirming clinical diagnosis of thrombosis
Ultrasound [8,37–39] 1 0.43 39 (25–100)
Lung perfusion & ventilation scans [8,37,39] 0 1 116 (116–168)
Angiogram [8,37–39] 0 0.14 1022 (511–1533)
Chest x-ray [8,37–39] 0 1 35 (15–48)
ECG [8,37] 0 1 9 (9–18)
Treatment of thrombosis, hospital re-admission
LMW heparin (5 inject. 
 

 
 100 PFS) [36] 5 5 7
Warfarin (weeks) [8,36] 12 12 0.42
Compression stockings class 3 (pairs) [8,36] 1 1 9 (9–11)
Physician time (hours) [8,41] 3 3 19 (16–39)
Nursing time (hours) [8,40] 3 3 12 (8–14)
Blood/platelet count [8,37,39] 1 1 3 (3–4)
Re-admission length of stay [18,38] 9 9 176 (88–264)
Intensive care days (50% PE patients) [8,37–39] 0 2 (0–2) 879 (879–988)
Treatment of thrombosis at home
LMW heparin (5 inject. 
 

 
 100 PFS) [36] 5 na 7
Warfarin (weeks) [8,36] 12 na 0.42
Compression stockings class 3 (pairs) [8,36] 1 na 9 (9–11)
District nurse visits [29] 8
 
†
 
na 13 (8–17)
Blood/platelet count [8,37,39] 1 na 3 (3–4)
 
*Base case estimates, numbers in parentheses are minimum and maximum values for the sensitivity analysis.
 
†
 
Assumed value for administration of enoxaparin and general patient care or monitoring.
DVT, deep vein thrombosis; PE, non-fatal pulmonary embolism; GP, general practitioner; ECG, electrocardiograph; LMW, low molecular weight; PFS, pre-filled syringes.
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ported in the clinical trial by Bergqvist et al. [18].
In the absence of data to the contrary, the follow-
ing assumptions were made. First, the length of
treatment for DVT for patients treated at home
was assumed to be the same as that for patients
admitted to hospital. Second, for the base case
analysis it was conservatively assumed that none
of the patients or their carers would administer
enoxaparin thromboprophylaxis themselves and
would require one district nurse visit per day of
thromboprophylaxis. This increases the costs of ex-
tended enoxaparin thromboprophylaxis, and may
over-estimate the total costs of this option. This
assumption was tested in the sensitivity analysis
by varying the proportion of patients or carers
who could administer enoxaparin thrombopro-
phylaxis from 0% to 100% [16,34,35]. Thirdly, it
was assumed that the cost of monitoring associ-
ated with warfarin therapy would be the same for
both groups and was excluded from the analysis.
However, the costs of weekly platelet counts to
monitor for drug-related adverse events were in-
cluded in the extended enoxaparin arm. The clini-
cal trials of extended enoxaparin did not identify
any statistically significant differences in hemato-
logical adverse events between the intervention
and control arms. On this basis these events were
excluded from the analysis. However, there may
be concern that extended enoxaparin could poten-
tially increase the risk of these events, leading to
increased use of laboratory based monitoring.
Finally, it was also assumed that all patients un-
dergoing elective hip replacement would have three
visits from a community-based health care profes-
sional to monitor progress. This may over-estimate
the costs of the standard enoxaparin group, and the
cost-effectiveness of extended enoxaparin. Again this
was tested in the sensitivity analysis, by excluding
the costs of these visits from the standard enox-
aparin group.
 
Unit Cost Data
 
The unit costs of enoxaparin (40 mg, 0.4 ml sy-
ringe) and warfarin, compression stockings, sy-
ringes and needles were estimated from the pub-
lished retail prices (Table 3) [36]. No allowance
was made for hospital discounts, which can vary
considerably between pharmacy departments.
The costs of blood tests, objective diagnosis
and hospital inpatient stay were estimated from
the tariffs of NHS provider units [37–39]. The costs
per hour of hospital-based health care professionals
were estimated from the reports of national review
bodies [40,41]. The costs of district nurse home vis-
its and general practitioner surgery consultations
were estimated from published costs [29].
 
Results
 
Table 4 presents the expected costs and outcomes
associated with the use of extended enoxaparin and
standard enoxaparin as prophylaxis for DVT. For
the base case analysis, the expected cost per 1000
individuals was £
 
428,139 for extended enoxaparin
and £
 
184,244 for standard enoxaparin, giving a net
cost of £
 
243,895 per 1000 people for extended
enoxaparin. In contrast, extended enoxaparin was
associated with a reduction in mortality and ex-
pected benefit of 6 lives gained per 1000 patients.
For the extended enoxaparin group, this translated
to a cost per life gained of £
 
42,898, cost per life-
year gained of £
 
4257 and cost per quality-adjusted
life-year (QALY) gained of £
 
5732.
 
Table 3
 
The costs of resource use per event (£
 
’s, 1997-98)
 
Average cost*
DVT PE
Thromboprophylaxis
Enoxaparin (post-discharge) 95 95
District nurse visits 265 265
GP visits 30 30
Blood platelet count 34 34
Total 400 400
No thromboprophylaxis
District nurse visits 38 38
GP visits 30 30
Total 68 68
Confirming clinical diagnosis of thrombosis
Ultrasound 39 17
Lung perfusion & ventilation scan 0 116
Angiogram 0 143
Chest x-ray 0 35
ECG 0 9
Total 39 319
Treatment of thrombosis, hospital re-admission
LMW heparin 36 36
Warfarin 5 5
Compression stockings class 3 (pairs) 9 9
Physician time (hours) 58 58
Nursing time (hours) 35 35
Blood/platelet count 3 3
Re-admission inpatient stay 1507 1507
Intensive care days (50% PE patients) 0 879
Total 1653 2532
Treatment of thrombosis at home
LMW heparin 36 na
Warfarin 5 na
Compression stockings class 3 (pairs) 9 na
District nurse visits 101 na
Blood/platelet count 3 na
Total 117 na
 
*Costs for the base case analysis, calculated as resource use multiplied by unit
cost, from Table 2.
GP, general practitioner; ECG, electrocardiograph; LMW, low molecular weight;
PE, non-fatal pulmonary embolism.
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The sensitivity analyses indicated a large range
in the net expected costs and benefits of extended
enoxaparin. The majority (88%) of the sensitivity
analyses estimated the cost per quality-adjusted
life-year gained to be below £
 
7000. The analysis
was sensitive to the values assigned to the percent-
age of patients or carers who could administer
enoxaparin injections at home, the rate of PE for
standard and extended enoxaparin and the rate of
DVT with standard enoxaparin. Figures 2–4 present
the results of the sensitivity analyses for these vari-
ables.
If more than 10% of patients or informal carers
could administer enoxaparin injections at home,
the expected cost/QALY gained would range be-
tween £
 
144 and £
 
5100 (Fig. 2). In contrast, it
could be assumed that only the rate of DVT will
vary between standard and extended enoxaparin,
and that the rate of PE, for patients with DVT is
the same for both thromboprophylaxis regimes
[3]. Figure 3 presents the results of the sensitivity
analysis for alternative rates of PE following DVT,
when it is assumed that the rate if PE is equivalent
between the two interventions. In this analysis, the
 
Table 4
 
Expected costs and outcomes of extended and standard enoxaparin, per 1000 patients
 
Expected cost & survival Incremental cost-effectiveness ratio
Extended enoxaparin Standard enoxaparin Cost/life gained Cost/life yr gained Cost/QALY gained
Discount rate 1.5% (base case)
Cost 428139 184244 42898 4257 5732
Survival 999 993
Life-years 10066 10009
QALYs 7476 7434
Discount rate 0%
Cost 428139 184244 42898 3900 5256
Survival 999 993
Life-years 10988 10926
QALYs 8153 8107
Discount rate 5%
Cost 428139 184244 42898 5164 6938
Survival 999 993
Life-years 8297 8250
QALYs 6176 6141
 
QALY: quality adjusted life year.
Figure 2 Sensitivity analysis: rate of self-administration of
extended thromboprophylaxis with enoxaparin.
Figure 3 Sensitivity analysis: equal rates of PE for standard
and extended enoxaparin.
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expected cost per QALY gained with extended
enoxaparin thromboprophylaxis could range from
£
 
4500 to £
 
27,000.
Finally, if the rate of DVT associated with stan-
dard thromboprophylaxis with enoxaparin is lower
than that found in the Bergqvist trial, then the ex-
pected cost/QALY gained by extended enoxaparin
will be between £
 
6000 and £
 
19,700 (Fig. 4). If the
rates of DVT from the trial by Planes et al. [19] are
used, the cost/QALY gained would be £
 
13,365.
 
Conclusions
 
The base case and sensitivity analyses indicated
that in most cases extended enoxaparin was asso-
ciated with increased costs for health care services,
when compared to standard enoxaparin. How-
ever, in all cases, extended enoxaparin was associ-
ated with net benefits in terms of improved sur-
vival and life-years gained.
These results need to be treated with caution.
The data used for the model were not collected
with the objective of estimating the cost-effective-
ness of extended enoxaparin. The majority of the
data for the model were point estimates from a
limited number of sources or derived from as-
sumptions. Given the nature of the data it was not
feasible to construct a valid stochastic simulation
model, which would have allowed statistical anal-
ysis of the results and corresponding measures of
uncertainty. This means that the results of the
model can only be indicative of the potential value
for money of using enoxaparin thromboprophy-
laxis for an extended period following discharge
for elective hip replacement.
The analysis did not include the impact of side
effects, primarily bleeding episodes, which may be
associated with the use of LMWH. There were no
statistically significant differences in these rates of
these adverse events in the clinical trials of ex-
tended prophylaxis with LMWH [18–21]. If there
were clinically or economically important differ-
ences in these events, then the cost-effectiveness of
extended enoxaparin may have been over-esti-
mated. However, the base case analysis did in-
clude the costs of additional monitoring for hema-
tological side-effects with extended enoxaparin.
Wherever possible, conservative assumptions were
used, to ensure that any biases in the analysis worked
against extended enoxaparin thromboprophylaxis.
These were further tested in the sensitivity analysis.
For those cases where extended enoxaparin was as-
sociated with a net expected cost, the cost per
quality-adjusted life-year gained ranged between
£
 
144 and £
 
27,000. These compare well with the
cost/QALY for other health care interventions
commonly used in the NHS (Table 5) [28].
In addition, a number of factors may mean that
enoxaparin is more cost-effective than the base
case analysis would indicate. First, it is plausible
that some patients on extended enoxaparin would
require fewer visits than assumed. There is some
evidence to suggest that patients or their carers can
administer enoxaparin thromboprophylaxis with-
out the assistance of a health care professional. The
proportions of patients found eligible for home
treatment ranges from 20 to 85% [16,34,35]. If
20% of patients could administer their own injec-
Figure 4 Sensitivity analysis: rates of DVT for standard
enoxaparin.
 
Table 5
 
Cost per quality-adjusted life year of
alternative interventions
 
Intervention Cost/QALY [28] (£’
 
s, 1990)
GP advice to stop smoking 270
Pacemaker implantation 1100
Cholesterol testing and treatment 1480
Extended thromboprophylaxis 4976*
Kidney transplant 4710
Breast cancer screening 5780
Heart transplant 7840
Home hemodialysis 17,260
Neurosurgery for malignant tumours 107,780
 
*The expected cost per QALY estimated in this evaluation.
GP: general practitioner.
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tions, the cost per quality-adjusted life-year gained
was reduced to £
 
4500. If 85% or more of patients
or carers could administer enoxaparin, extending
thromboprophylaxis to the postdischarge phase
would result in an expected cost/QALY of less
than £
 
1000. Secondly, the rate of clinical diagno-
sis of DVT used for the analysis may be low, com-
pared to current practice. If this were increased to
35% the analysis would show lower costs and
higher survival in the extended enoxaparin group
than the standard enoxaparin group.
Thirdly, the analysis only considered the short-
term implications of DVT and PE. However, DVT
can cause problems over a much longer period. Levin
et al. [42] estimated the extra cost of a DVT over 15
years to be roughly £
 
12,000 per person (converted to
UK £’
 
s and inflated to 1998 prices). Incorporating
these additional costs into the model would give a net
expected saving associated with extended enoxaparin
of approximately £
 
2300 per person.
Fourthly, the analysis weighted the life-years
gained from the prevention of DVT, by using a
utility measure to reflect the generally lower health-
related quality of life of older people. However,
the base case analysis assumed that people who
had DVT and survived would have the same life
expectancy and health-related quality of life as
those who did not have DVT. This may under es-
timate the long-term impact of DVT on health sta-
tus and morbidity. If extended enoxaparin throm-
boprophylaxis reduces the incidence of clinically
important DVT, the QALY gains will also have
been under-estimated.
Despite the limitations of analyses using model-
ling techniques, this conservative analysis indicates
that extended thromboprophylaxis with enoxaparin
may be cost-effective, compared to many other
routine interventions. This will depend in part, on
the monetary valuations health care policy-makers
place upon gains in survival and quality of life.
 
This work has been funded by Aventis Pharma, UK.
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